GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing
GRAIL (Nasdaq: GRAL) has launched Generation Possible, partnering with actress Kate Walsh to raise awareness about multi-cancer early detection (MCED) testing. The initiative highlights the significance of early cancer detection, with Walsh's involvement stemming from her parents' cancer experiences.
Key statistics reveal that 46% of Americans aged 50-75 worry about cancer diagnosis, and approximately 70% of cancer deaths are caused by cancers without recommended screening tests. When detected early, the overall 5-year survival rate is four times higher than late-stage diagnosis.
MCED tests serve as a new screening tool for multiple cancers lacking recommended screening tests today. Available at GenPossible.com, the initiative provides resources including Walsh's personal cancer connection, MCED testing information, and a quiz to determine testing appropriateness. These prescription-only tests are recommended for adults with elevated cancer risk, particularly those 50 or older, as a complement to existing cancer screenings.
GRAIL (Nasdaq: GRAL) ha lanciato Generation Possible, collaborando con l'attrice Kate Walsh per sensibilizzare sulla rilevazione precoce dei tumori attraverso il test MCED (multi-cancer early detection). L'iniziativa sottolinea l'importanza della diagnosi precoce del cancro, con il coinvolgimento di Walsh che deriva dalle esperienze di cancro dei suoi genitori.
Statistiche chiave rivelano che il 46% degli americani di età compresa tra 50 e 75 anni è preoccupato per una diagnosi di cancro, e circa il 70% dei decessi per cancro è causato da tumori per i quali non sono disponibili test di screening raccomandati. Quando viene diagnosticato precocemente, il tasso di sopravvivenza globale a 5 anni è quattro volte superiore rispetto a una diagnosi tardiva.
I test MCED fungono da nuovo strumento di screening per più tumori che attualmente non dispongono di test di screening raccomandati. Disponibile su GenPossible.com, l'iniziativa offre risorse che includono il legame personale di Walsh con il cancro, informazioni sui test MCED e un quiz per determinare l'adeguatezza del test. Questi test, disponibili solo su prescrizione, sono raccomandati per gli adulti con un rischio elevato di cancro, in particolare per quelli di età pari o superiore a 50 anni, come complemento agli screening oncologici esistenti.
GRAIL (Nasdaq: GRAL) ha lanzado Generation Possible, asociándose con la actriz Kate Walsh para crear conciencia sobre las pruebas de detección temprana de múltiples cánceres (MCED). La iniciativa resalta la importancia de la detección temprana del cáncer, y el involucramiento de Walsh proviene de las experiencias de cáncer de sus padres.
Estadísticas clave revelan que el 46% de los estadounidenses de 50 a 75 años se preocupa por un diagnóstico de cáncer, y aproximadamente el 70% de las muertes por cáncer son causadas por cánceres que no tienen pruebas de detección recomendadas. Cuando se detecta a tiempo, la tasa de supervivencia global a 5 años es cuatro veces mayor que en un diagnóstico en etapas avanzadas.
Las pruebas MCED sirven como una nueva herramienta de detección para múltiples cánceres que hoy en día carecen de pruebas de detección recomendadas. Disponibles en GenPossible.com, la iniciativa proporciona recursos que incluyen la conexión personal de Walsh con el cáncer, información sobre pruebas MCED y un cuestionario para determinar la idoneidad de la prueba. Estas pruebas, que solo se pueden obtener con receta, se recomiendan para adultos con un riesgo elevado de cáncer, especialmente aquellos de 50 años o más, como complemento a las pruebas de cáncer existentes.
GRAIL (Nasdaq: GRAL)은 Generation Possible을 출시하며, 배우 케이트 월시와 협력하여 다중 암 조기 발견(MCED) 테스트에 대한 인식을 높이고 있습니다. 이 이니셔티브는 조기 암 발견의 중요성을 강조하며, 월시의 참여는 그녀의 부모의 암 경험에서 비롯됩니다.
주요 통계에 따르면 50세에서 75세 사이의 미국인 중 46%가 암 진단에 대해 걱정하고 있으며, 약 70%의 암 사망이 권장 스크리닝 테스트가 없는 암으로 인해 발생합니다. 조기에 발견되면 전체 5년 생존율이 말기 진단보다 네 배 높습니다.
MCED 테스트는 현재 권장 스크리닝 테스트가 없는 여러 암에 대한 새로운 스크리닝 도구로 사용됩니다. GenPossible.com에서 이용할 수 있는 이 이니셔티브는 월시의 개인적인 암 연결, MCED 테스트 정보 및 테스트 적합성을 결정하는 퀴즈를 포함한 자원을 제공합니다. 이 처방전 전용 테스트는 특히 50세 이상인 암 위험이 높은 성인에게 기존 암 검진을 보완하는 형태로 권장됩니다.
GRAIL (Nasdaq: GRAL) a lancé Generation Possible, en s'associant à l'actrice Kate Walsh pour sensibiliser au dépistage précoce des cancers multiples (MCED). L'initiative souligne l'importance de la détection précoce du cancer, l'implication de Walsh provenant des expériences de cancer de ses parents.
Des statistiques clés révèlent que 46% des Américains âgés de 50 à 75 ans s'inquiètent d'un diagnostic de cancer, et environ 70% des décès par cancer sont causés par des cancers pour lesquels il n'existe pas de tests de dépistage recommandés. Lorsqu'il est détecté tôt, le taux de survie global à 5 ans est quatre fois plus élevé que celui d'un diagnostic à un stade avancé.
Les tests MCED servent d'outil de dépistage nouveau pour plusieurs cancers qui ne disposent pas actuellement de tests de dépistage recommandés. Disponibles sur GenPossible.com, l'initiative propose des ressources incluant le lien personnel de Walsh avec le cancer, des informations sur les tests MCED et un quiz pour déterminer l'adéquation du test. Ces tests, disponibles uniquement sur ordonnance, sont recommandés pour les adultes présentant un risque élevé de cancer, en particulier ceux de 50 ans ou plus, en complément des dépistages du cancer existants.
GRAIL (Nasdaq: GRAL) hat Generation Possible ins Leben gerufen und arbeitet mit der Schauspielerin Kate Walsh zusammen, um das Bewusstsein für die frühzeitige Erkennung von mehreren Krebsarten (MCED) zu schärfen. Die Initiative hebt die Bedeutung der frühen Krebsdiagnose hervor, wobei Walshs Engagement aus den Krebserfahrungen ihrer Eltern resultiert.
Wichtige Statistiken zeigen, dass 46% der Amerikaner im Alter von 50 bis 75 Jahren sich Sorgen um eine Krebsdiagnose machen und etwa 70% der Krebstodesfälle durch Krebsarten verursacht werden, für die keine empfohlenen Screening-Tests verfügbar sind. Bei frühzeitiger Erkennung ist die allgemeine 5-Jahres-Überlebensrate viermal höher als bei einer späten Diagnose.
MCED-Tests dienen als neues Screening-Tool für mehrere Krebsarten, für die es derzeit keine empfohlenen Screening-Tests gibt. Verfügbar unter GenPossible.com, bietet die Initiative Ressourcen, die Walshs persönliche Krebsverbindung, Informationen zu MCED-Tests und einen Quiz zur Bestimmung der Testangemessenheit umfassen. Diese Tests sind nur auf Rezept erhältlich und werden für Erwachsene mit erhöhtem Krebsrisiko, insbesondere für Personen ab 50 Jahren, als Ergänzung zu bestehenden Krebsvorsorgeuntersuchungen empfohlen.
- None.
- None.
Walsh has seen the devastating impact a cancer diagnosis can have through each of her parents' cancer journeys. These experiences led to her passion for living a healthy lifestyle, her commitment to getting her recommended cancer screenings and her advocacy for new health advances.
Cancer remains a major public health crisis and nearly half (
"Each of us would do whatever it takes for the ones we love, including protecting our health in any way we can. My parents didn't have an option to screen for multiple cancers beyond recommended screenings before there were symptoms," said Walsh. "I wish there had been a way to find my dad's cancer sooner because he may have had more options for treatment. This is the first generation that has access to multi-cancer early detection tests, in addition to recommended cancer screenings. I'm glad to be partnering with GRAIL on Generation Possible to help others understand the possibilities of MCED testing."
MCED tests are a new screening tool for multiple cancers that do not have recommended screening tests today.2,4 Health advancements have given today's generation access to new options that give more control when it comes to cancer screening.
"At GRAIL, we are driven by the potential of MCED testing to exponentially change the paradigm of cancer screening in this generation and those to come," said Josh Ofman, MD, MSHS, President at GRAIL. "Our research tells us that when most older Americans hear about the benefits of MCED testing, they want to learn more.3 We recognize our responsibility to educate more people, and we're thrilled to team up with Kate to drive awareness of the benefits of screening for multiple cancers."
More information about Generation Possible can be found at GenPossible.com, including Walsh's personal connection to cancer, details about MCED testing and access to important resources. Those considering MCED testing are able to take a quiz to determine if it may be appropriate for them and may choose to use the provided doctor discussion guide to communicate with their physician. MCED tests are prescription only tests, are recommended for adults with an elevated risk for cancer, such as those age 50 or older, and are to be used in addition to recommended cancer screenings.
About GRAIL, Inc.
GRAIL, Inc. is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
References:
- Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
- American Cancer Society. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, LLC. Data on file: GA-2021-0065]
- GRAIL survey, with data collection by Ipsos: n=1,000 US adults aged 50-75, fielded online between August 12 and 21, 2024. Sample was weighted to reflect
U.S. Census data (for Americans aged 50-75) on age, gender, race/ethnicity, income, and region. The sample has a credibility interval, a measure of precision for online polls, of plus or minus 3.8 percentage points. U.S. Preventive Services Task Force (USPSTF).Rockville, MD :U.S. Dept. of Health & Human Services, Agency for Healthcare Research and Quality. Recommended cancer screening tests, Grade A,B,C. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results.- Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence – SEER 18 Regs Research Data, 2018 Nov Sub. Includes persons aged 50-79 diagnosed 2006-2015. [GRAIL, LLC. Data on file: GA-2021-004]
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-partners-with-actress-kate-walsh-for-generation-possible-to-raise-awareness-of-multi-cancer-early-detection-testing-302383922.html
SOURCE GRAIL, Inc.
FAQ
What is the Generation Possible initiative by GRAL and how does it aim to improve cancer detection?
What are the survival rate differences for early vs. late cancer detection according to GRAL's research?
How many cancer deaths are caused by cancers without recommended screening tests?
Who is eligible for GRAL's multi-cancer early detection (MCED) testing?
What percentage of Americans aged 50-75 are concerned about cancer diagnosis?
